Replies to post #201598 on Biotech Values

[DewDiligence]

RETA +11% on planned phase-2/3 of Bardoxolone in CKD secondary to Alport syndrome:

http://finance.yahoo.com/news/reata-pharmaceuticals-inc-announces-third-133000259.html

Seems like the plan with Bardoxolone is to try enough indications that maybe one of them will stick.

Bardoxolone was once thought to be a blockbuster CKD drug for (pre-ABBV) ABT (#msg-54747777).